Citicoline

Citicoline Market Players are Capitalizing on Demand for Neuroprotective Drugs as Treatment of Choice for Neurological Disorders The citicoline market survey offers compelling insights into key factors impacting growth across key segments in terms of form, distribution channel, and indication. It also highlights strategies adopted by vendors to increase sales in citicoline market Fact.MR – A Market Research and Competitive Intelligence Provider: The global citicoline market registered 8% year on year growth in 2018, which is expected to rise further by 2028. Rising cases of glaucoma and retinal neurodegradation among geriatric population will remain a chief growth driver. Fact.MR in its latest study has predicted impressive growth on card for the market during its forecast period of 2018 and 2028. Increasing demand for nutraceuticals to improve cognitive functions due to adverse effects of long working hours and sleep deficiency will boost the market. Citicoline is increasingly finding usage in nutraceutical production owing to its neuroprotective properties and negligible toxicity. They are known to induce phospholipids in the brain required for proper functioning of neural pathways. Increasing cases of dementia, Alzheimer’s, and other neurological ailments are encouraging governments to support and increase investment in pharmaceutical sector for research and development activities. Extensive research to study citicoline’s efficacy in preventing and providing potential recovery from cognitive dysfunction is expected to provide growth opportunities for market players over the coming years. Request a report sample to gain comprehensive insights at Healthcare professionals are extensively researching on the usage of citicoline in preventing neurodegenerative deterioration of retina, which also will create growth opportunities for market. Similarly, role of citicoline in preventing conditions such as amblyopia, glaucoma, and neurodegradation are being investigated too. Researches studying the effects of citicoline application in the treatment of addictive disorders are expected to boost the market. Various studies suggest that citicoline has substantial influence on acetylcholine, glutamate, and dopamine. These are known to have potential to treat various symptoms of addiction disorders such as impaired cognitive functioning, withdrawal symptoms, and craving. On the back of these factors, the market is poised to expand at an impressive 8% CAGR through 2028. “Key players in the market are collaborating with pharmaceutical and healthcare industry to increase research on efficacy of citicoline with other chemicals. Players are thus, heavily investing in R&D of drugs based on diverse citicoline combinations for capitalizing on growing demand of neuroprotective drugs,” says the Fact.MR analyst. Key Takeaways The U.S. is expected to lead the growth across North America due to the high presence of leading players. Canada is likely to witness growth during forecast period owing to the rising investment in healthcare infrastructure and research activities on studying the potential of citicoline. China will lead Asia Pacific market on the back of rising cases of glaucoma and increasing research activities for the development of nutraceutical. Germany will dominate Europe’s citicoline market owing to the developed healthcare infrastructure and numerous research and development activities on neuroprotective drugs. Growth Drivers Hectic lifestyle, long working hours, and increasing are causing various health concerns, which in turn is improving the demand for nutraceutical. This will create growth opportunities for citicoline market through the forecast period. Government initiatives implemented to provide extended support for research and development of drugs to address Alzheimer’s and other neurological ailments will generate lucrative revenue for players operating in the global citicoline market. Ask Your Citicoline Market Related Questions & Get Customized Reports Competitive Landscape Presence of numerous leading players has led to intense competition in the market. Key players are adopting various growth strategies such as mergers, acquisitions, partnerships, collaborations, and product development. For instance, Kyowa Hakko Bio Co., Ltd., launched two novel citicoline powdered supplements and citicoline capsules in 2018 to capitalize rising demand for citicoline in functional foods. Some of the key players operating in the global citicoline market as profiled by Fact.MR are: Alfa Aesar Cepham, Inc. EZ Melts HL-Pharma US Double Wood LLC Instas Pharmaceuticals Ltd. Jarrow Formulas, Inc. Kimia Biosciences Rakshit Drugs Pvt., Ltd., Relentless Improvement LLC Swanson Wellona Pharma Private Limited Healthy Origins Biochemix Healthcare Pvt., Ltd. Merck KGaA Grupo Ferrer Internacional, S.A. Piping Rock Health Products, LLC NuerAxon Pharma Inc. More Insights on the Citicoline Market Fact.MR provides an unbiased analysis of the citicoline market presenting historical demand data (2013-2017) and forecast statistics for the period from 2018 to 2028. The study divulges into compelling insights on the citicoline market with detailed segmentation on the basis of: Form Tablet Powder Capsule Distribution Channel Hospital pharmacy Online channel Retail pharmacy Other channels By Indication Alzheimer’s Disease Dementia Head Trauma Cases Cerebral Ischemic Stroke Cognitive Impairments Attention Deficit-Hyperactive Disorder (ADHD) Glaucoma Others Regions North America Latin America Europe East Asia South Asia Oceania MEA Key Questions Covered in the Citicoline Market Report The report offers detailed insights into citicoline demand outlook for 2021-2031 The market study also highlights projected sales growth for citicoline market between 2021 and 2031 Citicoline market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends, evaluation of current market size, and technological advancements within the industry Citicoline market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others Explore Fact.MR’s Coverage on the Healthcare Domain – Rare Neurodegenerative Disease Treatment Market- Market participants are increasing their investments in medication development for the treatment of neurodegenerative diseases, and patients are becoming more aware of the various therapeutic choices available. In the long run, the rise in medical tourism and investments in modernizing healthcare infrastructure across Asia Pacific's developing countries are projected to benefit the rare neurodegenerative disease treatment market. Long-term growth will be aided by advances in medical technology for the diagnosis and treatment of various ailments. Glaucoma Therapeutics Market- A number of technical breakthroughs in drug delivery are expected to expand the spectrum of glaucoma therapeutics. Implantable extended-release devices, polymer-based contact lenses, and intraocular delivery technologies are among the innovations. These approaches are expected to improve glaucoma patients' quality of life and provide more effective medications for preserving eyesight in glaucoma patients. Prostaglandins are expected to find widespread usage for treating glaucoma among patients. Cognitive and Memory Enhancer Drugs Market- Supplements or simply medications that boost cognitive functioning improvement are known as cognitive and memory enhancer drugs. In the coming years, rising awareness of the benefits of cognitive and memory enhancer medications for improving mental and physical performance will increase demand. Nootropics are a new class of brain enhancer medications that are designed to give your brain an extra push. The increased popularity of nootropics, also known as smart drugs, is likely to boost the market for cognitive and memory enhancer drugs in the coming years. About Fact.MR Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology to even the most niche categories. 80% of Fortune 1000's trust us in critical decision making. MarketNgage is powered by Fact.MR – our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs. You can access all our healthcare research reports by signing up with MarketNgage’s Market Research Subscription with FREE credits. MarketNgage is powered by Fact.MR – A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies. Contact: Mahendra Singh US Sales Office 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: sales@factmr.com Source: Fact.MR

NEW YORK, April 13, 2021 /PRNewswire/ -- A chemical known to protect nerve cells also slows glaucoma, the leading cause of irreversible blindness, results of a new study in rats show. Led by researchers at NYU Grossman School of Medicine, the study centers on the watery fluid inside the eye on which its function depends. Fluid pressure can build up in patients with glaucoma, wearing down cells in the eye and the nerves connecting them to the brain, researchers say. However, past studies have shown the condition to continue to worsen even after eye pressure has been controlled. The connection between pressure buildup and impaired vision remains poorly understood. Publishing April 13 in Neurotherapeutics, the new study showed that ingesting the compound citicoline restored optic nerve (neural) signals between the brain and eye to near-normal levels in the study rats. Naturally produced in the brain but also available commercially, citicoline is a major source of choline, a building block in the membranes that line nerve cells and enhance nerve cell communication. While the study results confirmed past findings that elevated eye pressure contributes to nerve damage in glaucoma, it also showed that citicoline reduced vision loss in rats without reducing fluid pressure in the eye. "Our study suggests that citicoline protects against glaucoma through a mechanism different from that of standard treatments that reduce fluid pressure," says senior study author Kevin Chan, PhD, an assistant professor in the Department of Ophthalmology at NYU Langone Health. "Since glaucoma interrupts the connection between the brain and eye, we hope to strengthen it with new types of therapies." According to the National Glaucoma Foundation, over 3 million Americans have glaucoma, but only half know they actually have it. In the US, more than 120,000 individuals are blind from the disease. In addition, the World Health Organization estimates that over 60 million individuals suffer from glaucoma worldwide. The findings are helping scientists better understand how glaucoma works and add to past evidence that citicoline may counter the disease, says Chan, also the director of the Neuroimaging and Visual Science Laboratory at NYU Langone. Previous studies had showed that humans and rodents with glaucoma have lower than normal levels of choline in the brain. Until now, Chan says, there's been little concrete evidence of the effectiveness of choline supplements as a therapy for glaucoma or why choline occurs in lower levels in glaucoma patients. Chan and his team tested whether increasing levels of that chemical would slow or even stop the degradation of the optic nerve and other regions of the brain involved in vision. Using a comprehensive study of the eye-brain connection in glaucoma, his team found that giving rats oral doses of citicoline over a three-week period protected nerve tissues and reduced vision loss sustainably even after the treatment stopped for another three weeks. For the study, the researchers simulated glaucoma in several dozen rats using a clear gel to build up eye pressure mildly without otherwise blocking their vision. Then, the team measured the structural integrity and the amount of functional and physiological activity along the visual pathway using MRI scanning. The researchers also tracked the rodents' visual behavior to test the clarity of vision of each eye. The study showed that for rats with mildly elevated eye pressure, the tissues that connect the eye and brain, including the optic nerve, decayed for up to five weeks after the injury occurred. Meanwhile, nerve structure breakdown in the citicoline-treated rodents slowed by as much as 74 percent, which indicated that the chemical had protective effects on nerve cells, say the authors. The researchers caution that more research is needed before turning to citicoline supplements to treat glaucoma in humans, as commercial drugs have yet to be proven fully effective in clinical trials. Moving forward, the researchers plan to investigate the origin of choline decline in people with glaucoma as well as how citicoline works to repair the damage. Funding for the study was provided by National Institutes of Health grant R01 EY028125, a Liesegang Fellowship, a Research to Prevent Blindness/Stavros Niarchos Foundation International Research Collaborators Award; and an Unrestricted Grant from Research to Prevent Blindness to NYU Langone Health's Department of Ophthalmology. In addition to Chan, other NYU Langone researchers included Jeffrey R. Sims, BS; Gadi Wollstein, MD; and Joel S. Schuman, MD. Other researcher support was provided by Yolandi van der Merwe, PhD; Matthew C. Murphy, PhD; Xiao-Ling Yang, MD; Leon C. Ho, PhD; and Ian P. Conner, MD, PhD, at the University of Pittsburgh. Yu Yu, PhD, at Hong Kong University of Science and Technology in Hong Kong, and Christopher K. Leung, MD, at the Chinese University of Hong Kong provided further research support. Media Inquiries Shira Polan 212-404-4279 shira.polan@nyulangone.org View original content to download multimedia: SOURCE NYU Grossman School of Medicine